All Oncology News

T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A ctDNA blood test predicted metastatic risk, but not local recurrence, after bladder-sparing cancer treatment.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

Data from KEYNOTE-B96 supported the first FDA approval of an immunotherapy regimen in PD-L1–positive platinum-resistant, recurrent ovarian cancer.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

Tycel Phillips, MD, discusses key questions on optimal BTK inhibitor strategies in mantle cell lymphoma.

Allo-HSCT did not improve survival outcomes in patients with lower-risk myelodysplastic syndrome who had some higher-risk features.

Treatment with subcutaneous amivantamab plus pembrolizumab was deemed effective and safe in patients with recurrent or metastatic, PD-L1–positive HNSCC.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center appointed new members to advance the institute’s immunotherapy work.

Igor Makhlin, MD, notes the imaging modalities used in metastatic breast cancer and highlights FES-PET/CT as a specific modality for ER-positive disease.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

Pirtobrutinib has been approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma in China.

Serial liquid biopsies consistently showed AR alterations linked to poorer outcomes, and findings support “real-time” molecular testing to guide personalized care.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

KEYNOTE-B96 showed that pembrolizumab plus paclitaxel improved PFS and OS vs chemotherapy alone in platinum-resistant ovarian cancer.

Induction ipilimumab plus nivolumab followed by consolidative chemoradiotherapy led to bladder preservation in stage 2/3 urothelial carcinoma of the bladder.

Will the FDA approve rusfertide for the treatment of adult patients with polycythemia vera?

The FDA has tentatively approved the abbreviated new drug application for the lutetium lu 177 dotatate radioequivalent PNT2003 in SSTR-positive GEP-NETs.

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Maurie Markman, MD, discusses ethical dilemmas in oncology trials, balancing patient welfare with research integrity and regulatory goals.

A new study suggests that blocking the survival response after PARP inhibitor treatment could bolster their efficacy in ovarian cancer.

The addition of palbociclib to belzuitfan was not associated with improved responses in pretreated clear cell renal cell carcinoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.